Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

Equecabtagene autoleucel produced “remarkable” responses in patients whose disease progressed after prior BCMA CAR T-cell therapy, researchers reported.

GSK reported positive survival data for Blenrep combined with bortezomib and dexamethasone in multiple myeloma DREAMM-7 trial, outperforming daratumumab combination therapy. GSK plans US relaunch in ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

Patients with metastatic non-small cell lung cancer, even those with brain metastases ... results showed that patients on the ...

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

A new study finds that pathogenic germline variants (PGVs) in cancer predisposition genes like BRCA1 and BRCA2 increase the risk of multiple ...

Multiple Myeloma is a type of blood cancer that develops in plasma cells — white blood ... and advanced therapies like blood ...

and liver cancer. The 1-year relative survival rate for all cancers combined fell from 82.3% in the second quarter of 2018 to ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Another BiTE in development by Amgen binds CD3 on T cells to STEAP1 on prostate cancer cells. In a preliminary clinical study ...